April 1, 2026: Patient Form Temporary Outage Notice – Patient forms will be unavailable tonight from 9:00 PM – 5:00 AM EST due to scheduled maintenance. Access will be restored on April 2, 2026, by 6:00 AM EST. Thank you for your patience.
A human plasma-derived, polyclonal, intravenous immunoglobulin G (IgG) formulation containing high levels of antibodies against hepatitis C virus (HCV), a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, with potential immunomodulating and antiviral activities. The hepatitis C IgG is isolated from donors expressing high amounts of HCV antibodies. Upon intravenous administration, the anti-HCV antibodies bind to the virus and provide passive immunization against HCV. This may prevent both infection by HCV in immunocompromised patients and hepatitis C-related liver disease. The polyclonal anti-HCV antibodies are able to target various viral epitopes. Check for active clinical trials using this agent. (NCI Thesaurus)